Viking Therapeutics Inc. announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial evaluating subcutaneous VK2735 for the treatment of obesity. Enrollment was completed ahead of schedule and exceeded the target size. VK2735 is a dual agonist of the GLP-1 and GIP receptors and is being developed in both oral and subcutaneous formulations for metabolic disorders such as obesity. The VANQUISH-1 trial's primary endpoint is the percent change in body weight from baseline compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints include the proportion of patients achieving various thresholds of body weight reduction and additional safety and efficacy measures. A 52-week extension period is also included for continued treatment. Viking Therapeutics is concurrently conducting the Phase 3 VANQUISH-2 study of subcutaneous VK2735 in patients with type 2 diabetes who have obesity or are overweight, with enrollment expected to complete in the first quarter of 2026. Previously, in 2024, Viking announced positive results from the Phase 2 VENTURE study of VK2735 in obesity, where the drug met its primary and secondary endpoints, demonstrating significant reductions in body weight compared to placebo and favorable safety and tolerability profiles. Results from the ongoing Phase 3 studies have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA28031) on November 19, 2025, and is solely responsible for the information contained therein.
Comments